A proof of concept, multi-centre evaluation of the potential beneficial effects of CB0011 when combined with CB0012 for the treatment of obstructive sleep apnea.
Phase of Trial: Phase I/II
Latest Information Update: 17 Jun 2016
At a glance
- Drugs CB 0011 (Primary) ; CB 0012 (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- Sponsors Cypress Bioscience
- 29 Aug 2011 Status changed from active, no longer recruiting to completed as reported by Australian New Zealand Clinical Trials Registry Record.
- 26 Jul 2011 New trial record